A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Rationale : Nonalcoholic steatohepatitis (NASH) is a common disease that is associated
with increased morbidity and mortality, with limited treatment options. The efficacy and
safety of the glucagon-like peptide-1 receptor agonist semaglutide in NASH is unknown.

Infographic

Reference

Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021 Mar 25;384(12):1113-1124.

>